Keyword: Ibrance

Takeda's dengue vaccine clears phase 3; Pfizer launches China's first pay-for-performance deal in oncology; Aslan cuts 30% of its workforce.

In a first, Pfizer promises reimbursement of up to 33.5% of Ibrance costs for eligible Chinese breast cancer patients.

NICE initially told Eli Lilly that its breast cancer drug Verzenio wasn't cost-effective. So Lilly dished up a price break—and it worked.

A new look at cancer survivors' media habits shows that where they get data and to what degree they value it depends on when they were diagnosed.

Integration following a large-scale M&A is too much a distraction from Pfizer's "best pipeline in our history," said Bourla.

A pile of evidence for CDK 4/6 cancer drugs hasn’t yet persuaded some physicians to try the meds, but Pfizer's going all out to change their minds.

Pfizer’s Ibrance failed to prove it could help some patients live longer, but executives say those study results still make a “compelling” case.

Lilly did not make a plausible case that its drug is more cost-effective than other CDK 4/6 inhibitors, England's drug-price watchdog said.

As a big ESMO 2018 kicks off, here are the studies we're most excited to see.